A ‘very good year’ for Roche

Roche has announced results of its 2013 full-year financial performance, including a 6% rise in sales, to 46.8 billion Swiss francs (about £31.5 billion).

The company has a positive outlook for 2014: it expects sales to grow at low- to mid-single digit rates. It also expects core earnings per share to grow, and to further increase its dividend.

"2013 was a very good year for Roche.

"We exceeded our financial targets with strong demand for our existing products and positive uptake of recently launched medicines and diagnostics.

"With the launch of Perjeta and Kadcyla we have added a new generation of treatments for women with a particularly aggressive type of breast cancer.

"With our strong product pipeline we are well positioned for future success."

Severin Schwan, chief executive, Roche.

Related news:

Roche sees 2014 profit, sales rising on new cancer drugs (Bloomberg).

Strong franc weighs on profits at drugmaker Roche (Reuters).

Reference link:

Roche delivers strong 2013 results (Roche press release).